Clinical trials: Neuroendocrine Tumor Metastatic
Merkel Cell Carcinoma, Skin Cancer
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
This is an open-label, non-randomized, phase 2 study to assess the feasibility of using cabozantinib in recurrent/metastatic Merkel Cell Carcinoma patients that progressed after platinum-based therapy.
- Trial name
- NCT02036476
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer.
- Trial name
- NCT00049010
- Testing
- comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
- Where
- 27 sites in United States
- Volunteers
- 314 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body.
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma
- Trial name
- NCT06176989
- Testing
- Enasidenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate LYL845 in Adults With Solid Tumors
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05573035
- Testing
- LYL845
- Where
- 18 sites in United States
- Volunteers
- 39 people
- Sponsor
- Lyell Immunopharma, Inc.
Melanoma
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma
- Trial name
- CheckMate 066 (NCT01721772)
- Testing
- BMS-936558 (Nivolumab), Dacarbazine
- Where
- 75 sites in Argentina, Australia and 14 more
- Volunteers
- 418 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
MB-CART20.1 Melanoma
This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients.
- Trial name
- NCT03893019
- Testing
- MB-CART20.1
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Miltenyi Biomedicine GmbH
Advanced Hepatocellular Carcinoma, Advanced Melanoma
Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer
This clinical trial tests the effect of multiple therapies (propranolol, desloratadine, and magnesium and vitamin D supplements) added to primary standard of care immunotherapy (adjunct), as well as adjusting the timing of…
- Conditions
- Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma
- Trial name
- NCT07836712
- Testing
- Biospecimen Collection, Cholecalciferol, Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Southern California
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Melanoma Stage III, Melanoma Stage IV
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
Currently, standard treatment options available for Stage III melanoma include locoregional management (i.e. surgery) or systemic treatment (adjuvant to surgery or primarily in the case of unresectable disease).
- Trial name
- NIVEC (NCT04330430)
- Testing
- T-VEC
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Ganglioneuroblastoma, Ganglioneuroma
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
This trial studies how well an investigational scan called 68Ga-DOTATATE PET/CT works in diagnosing pediatric patients with neuroendocrine tumors that have spread to other places in the body (metastatic).
- Conditions
- Ganglioneuroblastoma, Ganglioneuroma, Neuroblastoma
- Trial name
- NCT04040088
- Testing
- Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Liver Metastases, Liver Metastasis Colon Cancer
DNX-2440 for Resectable Colorectal Liver Metastasis
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery.
- Conditions
- Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04714983
- Testing
- DNX-2440
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DNAtrix, Inc.
Melanoma
IL2 Imaging in Metastatic Melanoma
T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types.
- Trial name
- NCT02922283
- Testing
- IL2-PET scan, Tumor biopsy, CT scan
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- University Medical Center Groningen
Gastroenteropancreatic Neuroendocrine Tumors
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut…
- Trial name
- EXPLAIN (NCT02630654)
- Testing
- This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- Where
- 25 sites in Denmark, Estonia and 5 more
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Ipsen
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Melanoma
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic…
- Trial name
- NCT00107718
- Testing
- SB-485232
- Where
- 20 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only.
- Trial name
- NCT00121680
- Testing
- E7080
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- Eisai Inc.
Melanoma, Uveal Metastatic
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy.
- Trial name
- NCT04335890
- Testing
- Vaccination with IKKb matured Dendritic Cells
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Hasumi International Research Foundation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic…
- Conditions
- Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
- Trial name
- NCT06208124
- Testing
- IMM-6-415
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immuneering Corporation
Malignant Melanoma
Melanoma Metastasized to the Brain and Steroids
This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit for MM patients with brain metastases and in need…
- Trial name
- MEMBRAINS (NCT03563729)
- Testing
- Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo]
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Inge Marie Svane
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.